Table 2.
Metabolic and other parameters at baseline and after 12 weeks.
| Parameters | Placebo controls | Pioglitazone | ||
|---|---|---|---|---|
| 0 wk | 12 wk | 0 wk | 12 wk | |
| Body mass index, kg/m2 | 23.7 ± 4.9 | 23.3 ± 3.3 | 24.5 ± 2.9 | 24.7 ± 2.5 |
| Weight, kg | 65.4 ± 12.7 | 66.7 ± 12.7 | 68.8 ± 9.4 | 69.3 ± 8.3 |
| Waist to hip ratio, % | 89.1 ± 5.8 | 89.3 ± 5.6 | 89.9 ± 5.9 | 90.2 ± 5.5 |
| Systolic BP, mm Hg | 124 ± 19 | 126 ± 13 | 121 ± 16 | 121 ± 15 |
| Diastolic BP, mm Hg | 78 ± 10 | 77 ± 8 | 76 ± 10 | 73 ± 9 |
| Fasting glucose, mmol/L | 5.28 ± 0.57 | 5.30 ± 0.49 | 5.32 ± 0.37 | 5.31 ± 0.45 |
| Fasting insulin, U/L | 6.73 ± 3.98 | 6.10 ± 4.02 | 6.79 ± 4.44 | 5.21 ± 3.62 |
| HbA1c, % | 5.42 ± 0.59 | 5.72 ± 0.46 | 5.18 ± 0.49 | 5.79 ± 0.35 |
| Total cholesterol, mmol/L | 3.78 ± 0.76 | 3.12 ± 0.74∗∗ | 3.61 ± 0.45 | 3.01 ± 0.51∗∗ |
| Triglycerides, mmol/L | 1.75 ± 1.27 | 1.38 ± 0.91∗ | 1.81 ± 1.23 | 1.14 ± 0.39∗ |
| HDL cholesterol, mmol/L | 0.90 ± 0.17 | 1.16 ± 0.41∗ | 0.88 ± 0.20 | 1.27 ± 0.41∗∗ |
| LDL cholesterol, mmol/L | 2.35 ± 0.67 | 1.67 ± 0.40∗∗ | 2.15 ± 0.49 | 1.69 ± 0.40∗ |
| hsCRP, mg/L | 4.0 (0.9, 11.8) | 2.2 (0.8, 6.8)∗∗ | 2.9 (1.3, 12.3) | 1.0 (0.5, 3.8)∗∗# |
| NT-pro BNP, pg/mL | 220 (79, 839) | 231 (140, 664) | 259 (73, 706) | 260 (102, 703) |
| EF, % | 61.3 ± 9.9 | 62.7 ± 9.5 | 60.4 ± 8.1 | 60.6 ± 7.4 |
n = 14 for each group. Values are mean ± SD or median (interquartile range).
∗ P < 0.05 and ∗∗ P < 0.01 compared with baseline, and # P < 0.01, compared with the placebo group.